Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome Clinical research trials and VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome. VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome clinical trial. Participants frequently obtain the most expert healthcare available for their VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.

Home > "V" Clinical Trials Conditions > VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome

VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome



VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome

For Condition: Hairy Cell Leukemia,atypical chronic myeloid leukemia,myelodysplastic and myeloproliferative disease,Prolymphocytic Leukemia,chronic leukemia,acute leukemia
Status: No longer recruiting
Sponsor(s): Vion Pharmaceuticals ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have relapsed or refractory leukemia or myelodysplastic syndrome.
Details: OBJECTIVES: - Determine the toxic effects of VNP40101M in patients with relapsed or refractory leukemia or poor-risk myelodysplastic syndromes. - Determine the maximum tolerated dose of this drug in these patients. - Determine the pharmacokinetics of this drug in these patients. - Determine the antitumor effects of this drug in these patients. OUTLINE: Patients receive VNP40101M IV over 15 minutes once every 4 weeks. PROJECTED ACCRUAL: Approximately 40 patients will be accrued for this study.
Eligibility:
Study Type:
  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Relapsed or refractory leukemia for which no standard therapy is anticipated to result in a durable remission OR - Poor-risk myelodysplastic syndromes PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-1 Life expectancy - Not specified Hematopoietic - Not specified Hepatic - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - AST and ALT no greater than 3 times ULN Renal - Creatinine no greater than 2.0 mg/dL Cardiovascular - No myocardial infarction within the past 3 months - No symptomatic coronary artery disease - No uncontrolled arrhythmia - No uncontrolled congestive heart failure Other - No uncontrolled active infection PRIOR CONCURRENT THERAPY: Biologic therapy - Prior biologic therapy allowed Chemotherapy - At least 2 weeks since prior myelosuppressive cytotoxic chemotherapy in the absence of rapidly progressing disease - At least 48 hours since prior hydroxyurea Endocrine therapy - Not specified Radiotherapy - Prior radiotherapy allowed Surgery - Not specified Other - No other concurrent standard or investigational treatment for leukemia - No concurrent disulfiram
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
MarioSznol,  Study Chair,  Vion Pharmaceuticals

University of Texas - MD Anderson Cancer Center
Houston,  Texas,  77030-4095
United States
 


Additional Information:
Study ID Numbers:
  CDR0000258354;  VION-CLI-029,MDA-DM-02202
Study Start Date: 
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00049686

Other Prolymphocytic Leukemia Studies:
1. 3-AP and Cytarabine in Treating Patients With Hematologic Cancer

2. Bone Marrow Transplantation in Treating Patients With Hematologic Cancers

3. Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia

4. Bone Marrow Transplantation Plus Cyclophosphamide and Radiation Therapy in Treating Patients With Hematologic Cancer

5. MS-275 in Treating Patients With Hematologic Cancer

Related Studies:

Other Prolymphocytic Leukemia Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials

VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome

Modify your Search

  Other Prolymphocytic Leukemia Clinical Trials
  Other Texas Clinical Trials
  Other Houston Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103